Akebia Therapeutics, Inc.
US ˙ NasdaqCM ˙ US00972D1054

SecurityAKBA / Akebia Therapeutics, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership921,923 shares
Latest Disclosed Value $ 1,280,467
Dimensional Fund Advisors Lp reports 41.32% decrease in ownership of AKBA / Akebia Therapeutics, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 921,923 shares of Akebia Therapeutics, Inc. (US:AKBA) valued at $1,281,473 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 1,571,012 shares of Akebia Therapeutics, Inc.. This represents a change in shares of -41.32% during the quarter. The current value of the position is $862,275 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F AKEBIA THREAPEUTICS COM 00972D105 921,923 -649,089 -41.32 1,280 -49.37 0.0003
2026-02-12 2025-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 1,571,012 -195,679 -11.08 2,529 -47.57 0.0005
2025-11-12 2025-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 1,766,691 884,590 100.28 4,823 50.17 0.0010
2025-08-12 2025-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 882,101 346,670 64.75 3,211 212.66 0.0007
2025-05-13 2025-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 535,431 409,751 326.03 1,028 331.51 0.0003
2025-02-13 2024-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 125,680 125,680 239 0.0001
2023-02-09 2022-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -627,549 -100.00 0 -100.00
2022-11-10 2022-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 627,549 -155,126 -19.82 199 -27.90 0.0001
2022-08-12 2022-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 782,675 -1,884,186 -70.65 276 -85.59 0.0001
2022-05-13 2022-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 2,666,861 73,020 2.82 1,915 -67.33 0.0006
2022-02-09 2021-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 2,593,841 498,078 23.77 5,862 -2.88 0.0018
2021-11-12 2021-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 2,095,763 -1,309,358 -38.45 6,036 -53.23 0.0019
2021-08-12 2021-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 3,405,121 972,862 40.00 12,906 56.80 0.0041
2021-05-14 2021-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 2,432,259 684,955 39.20 8,231 68.19 0.0027
2021-03-08 2020-12-31 13F/A-2 AKEBIA THERAPEUTICS COM 00972D105 1,747,304 -10,432 -0.59 4,894 10.95 0.0018
2021-02-11 2020-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 1,747,304 -10,432 4,894 1,767.4527
2020-11-12 2020-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 1,757,736 -141,985 -7.47 4,411 -82.90 0.0019
2020-08-13 2020-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 1,899,721 55,298 3.00 25,794 84.49 0.0113
2020-05-14 2020-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 1,844,423 286,869 18.42 13,981 42.03 0.0073
2020-02-14 2019-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 1,557,554 301,930 24.05 9,844 99.96 0.0036
2019-11-12 2019-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 1,255,624 203,888 19.39 4,923 -3.28 0.0019
2019-08-13 2019-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 1,051,736 162,755 18.31 5,090 -30.10 0.0020
2019-08-12 2019-03-31 13F/A-2 AKEBIA THERAPEUTICS COM 00972D105 888,981 -53,618 -5.69 7,282 39.72 0.0029
2019-05-10 2019-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 888,981 -53,618 7,282
2019-02-26 2018-12-31 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 942,599 488,972 107.79 5,212 30.10 0.0024
2019-02-13 2018-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 942,599 488,972 5,212
2018-11-13 2018-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 453,627 453,627 4,006 0.0015
2018-02-12 2017-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -35,572 -100.00 0 -100.00
2017-11-13 2017-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 35,572 0 0.00 700 36.99 0.0003
2017-08-11 2017-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 35,572 0 0.00 511 56.27 0.0002
2017-05-12 2017-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 35,572 -3,391 -8.70 327 -19.46 0.0002
2017-02-09 2016-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 38,963 1,464 3.90 406 19.76 0.0002
2016-11-10 2016-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 37,499 12,527 50.16 339 81.28 0.0002
2016-08-09 2016-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 24,972 -93 -0.37 187 -17.26 0.0001
2016-05-13 2016-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 25,065 4,300 20.71 226 -15.67 0.0001
2016-02-10 2015-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 20,765 20,765 268 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.